Skip to content
Bored Studies
RecruitingPhase 2

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

Hanmi Pharmaceutical Company Limited · NCT07527650

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
180
US sites recruiting
20
Study start
May 18, 2026
Record last updated
October 19, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.

Being studied: HM15275; Placebo of HM15275

Conditions: Type 2 Diabetes Mellitus; T2DM

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Participant's age at the time of signing the informed consent:
  • United States: 18 to 75 years (inclusive)
  • Diagnosed with type 2 diabetes mellitus (T2DM) with HbA1c ≥7.0% and ≤10.0% at screening
  • Treated with diet and exercise alone or on a stable dose of metformin (≥1000 mg/day) for at least 3 months prior to screening
  • BMI ≥25 kg/m² and ≤50 kg/m²
  • Body weight change \<5% over the past 3 months prior to screening
  • Capable of giving signed informed consent and willing to comply with all protocol procedures

Key Exclusion Criteria

  • Type 1 diabetes mellitus or use of glucose-lowering medications other than metformin within 3 months prior to screening
  • Poor glycemic control (fasting plasma glucose >270 mg/dL)
  • History of diabetic ketoacidosis or severe hypoglycemia within 6 months
  • Clinically significant cardiovascular disease (e.g., NYHA class III/IV heart failure, recent myocardial infarction, stroke, or revascularization within 3 months)
  • History of pancreatitis or factors increasing the risk of pancreatitis
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2
  • Clinically significant liver disease, renal impairment (eGFR \<60 mL/min/1.73 m²), or abnormal laboratory findings at screening
  • Participation in another investigational study within 30 days or within 5 half-lives of the investigational product, whichever is longer; for GLP-1 receptor agonist-related or weight loss studies, participation within 3 months prior to screening

Recruiting US locations

  • Desert Clinical Research

    Mesa, AZ 85123

    Site contact: Gerald Shockey

  • Care Access Research - Santa Clarita

    Santa Clarita, CA 91321

    Site contact: Sina Tebi

  • Accel Research Sites - DeLand

    DeLand, FL 32720

    Site contact: Bruce Rankin

  • Charter Research

    Orlando, FL 32803

    Site contact: Mary Hilal Quarterman

  • AdventHealth Translational Research Institute

    Orlando, FL 32804

    Site contact: Richard Edwin Pratley

  • K2 Medical Research The Villages LLC

    The Villages, FL 32159

    Site contact: Craig T Curtis

  • Charter Research - The Villages

    The Villages, FL 32162

    Site contact: Stephen Mark Miller

  • Centricity Research IRT - DBA IACT Health Columbus Piedmont

    Columbus, GA 31904

    Site contact: Steven Leichter

  • Charter Research - Chicago

    Chicago, IL 60618

    Site contact: Tiffany Nguyen

  • The South Bend Clinic

    South Bend, IN 46617

    Site contact: Rita Schmid

  • Jefferson City Medical Center

    Jefferson City, MO 65109

    Site contact: Benjamin Cook

  • Clay Platte Family Medicine

    Kansas City, MO 64151

    Site contact: Scott Kuennen

  • Methodist Physicians Clinic

    Fremont, NE 68025

    Site contact: Thomas Wolf

  • Santa Rosa Medical Centers of Nevada

    Las Vegas, NV 89119

    Site contact: Syed Pervaiz

  • Lucas Research, Inc.

    Morehead City, NC 28557

    Site contact: Kathryn Jean Lucas

  • Centricity Research Columbus

    Columbus, OH 43213

    Site contact: Sridhar Guduri

  • DM Clinical Research

    Tomball, TX 77375

    Site contact: Muhammad Irfan

  • Olympus Family Medicine

    Salt Lake City, UT 84117

    Site contact: Jared Probst

  • Highland Clinical Research

    Salt Lake City, UT 84124

    Site contact: Derek Muse

  • Manassas Clinical Research Center

    Manassas, VA 20110

    Site contact: Nabil Saleh Andrawis

Study contacts (from the official record)

  • Pureun Nam · +82-2-410-9147 · pureun.nam@hanmi.co.kr
  • Hyeonho Choi · +82-2-410-9834 · hyeonho.choi@hanmi.co.kr
All diabetes studies in Arizona →
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus (NCT07527650) | Bored Studies